Arcturus and CSL's Innovative COVID-19 Vaccine Results
CSL Limited and Arcturus Therapeutics have recently revealed exciting outcomes from a Phase 3 clinical trial involving their sa-mRNA COVID-19 vaccine, ARCT-154. This study placed it head-to-head against Pfizer Inc's Comirnaty vaccine. The results indicate that ARCT-154 exhibits a remarkable ability to generate an immune response compared to the traditional mRNA vaccine.
Study Highlights
The trial showcased that ARCT-154 retained superior immunogenicity for up to one year against various COVID-19 strains, including the Wuhan-Hu-1 and Omicron BA.4-5 variants. Notably, it was administered at one-sixth of the dose compared to Comirnaty, using 5 ?g versus 30 ?g respectively. This remarkable finding underscores the efficiency and potential of the sa-mRNA technology.
Key Immune Response Findings
At Day 29 of the study, participants receiving ARCT-154 produced a higher level of neutralizing antibodies against the Wuhan-Hu-1 strain than those who received Comirnaty. The geometric mean titers (GMTs) indicated a rate of 5390 for ARCT-154 in comparison to 3738 for Comirnaty, resulting in a GMT ratio of 1.44. Importantly, this advantage extended through the trial’s duration, which included a follow-up at Day 361, showing GMTs of 3396 in the ARCT-154 group versus 1771 in the Comirnaty group, further proving its efficacy with a GMT ratio of 1.92.
Omicron Variant Response
Additionally, the vaccine’s performance against the Omicron BA.4-5 variant showcased impressive results, with GMT ratios of 1.31 at Day 29 and 1.89 at Day 361, which indicates sustained immune responses even as variants evolve.
Future Developments with ARCT-2301
Excitingly, CSL and Arcturus also revealed data on their bivalent formula, ARCT-2301, crafted on the same platform as ARCT-154. This formula also demonstrated superior immunogenicity compared to the conventional Comirnaty against key variants for up to six months post-vaccination. This positions ARCT-2301 as a promising candidate for COVID-19 immunization.
Trial Comparisons Between ARCT-2301 and Comirnaty
The recent data collected from a sample of 930 participants revealed that ARCT-2301 elicited better neutralizing antibody responses compared to Comirnaty. Notable GMT ratios were reported as 1.49 against Omicron BA.4-5 and 1.45 against the Wuhan-Hu-1 strain. Even six months post-vaccination, the GMT ratios remained strong at 2.17 and 1.98, respectively.
Commercialization and Approval Updates
ARCT-154, which is aimed at providing greater protection against COVID-19, has received approval for use in adults over 18 years in certain regions, marketed under the name Kostaive. As vaccination efforts continue globally, the advantages presented by this vaccine could play a significant role in public health by offering enhanced protection against the virus and its variants.
Increasing Market Activity
Following these groundbreaking study results, the stock prices for Arcturus, represented as ARCT, had shown a growth of 4.70%, reaching $23.07, marking favorable conditions for investors and stakeholders eager to witness the commercial viability of the new vaccine.
Frequently Asked Questions
What is ARCT-154?
ARCT-154 is a self-amplifying mRNA COVID-19 vaccine developed by Arcturus Therapeutics in collaboration with CSL Limited.
How does ARCT-154 compare to Comirnaty?
The Phase 3 trial showed that ARCT-154 has superior immunogenicity at a lower dosage compared to Comirnaty for various COVID-19 variants.
What does the Phase 3 study indicate?
The study indicates that ARCT-154 maintains a strong immune response against COVID-19 variants for up to one year after vaccination.
What are the implications of the ARCT-2301 findings?
ARCT-2301, a bivalent vaccine, demonstrated even better immune responses compared to Comirnaty, persisting over six months post-vaccination against key variants.
What is the approval status of these vaccines?
ARCT-154 is approved for use in adults over 18 years in specific regions, sold under the trade name Kostaive.
